表紙
市場調査レポート

血栓症:パイプライン製品の分析

Thrombosis - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 245970
出版日 ページ情報 英文 280 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
血栓症:パイプライン製品の分析 Thrombosis - Pipeline Review, H2 2015
出版日: 2015年11月30日 ページ情報: 英文 280 Pages
概要

血栓症は、血管の内側にできる血栓です。症状は、脈拍不足、筋肉の痛みやけいれん、青ざめた肌や冷感などがあります。血栓が生じる場所によっては、脳卒中、心臓発作、末梢動脈疾患(PAD)など、血栓症が深刻な状態を引き起こす可能性があります。素因として、喫煙、肥満、糖尿病、高血圧、高コレステロール値が挙げられます。治療には、血栓溶解療法や手術などが行われます。

当レポートでは、血栓症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向などについて、体系的な情報を提供しています。

目次

イントロダクション

血栓症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Archemix Corp.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Cardax Pharmaceuticals, Inc.
  • CSL Limited
  • Daewoong Pharmaceutical Co., Ltd.
  • IMMD Inc.
  • Isis Pharmaceuticals, Inc.
  • LG Life Sciences, Ltd.
  • Lipicard Technologies Limited
  • Medicure Inc.
  • Merck & Co., Inc.
  • MSM Protein Technologies, Inc.
  • Nostrum Pharmaceuticals, LLC
  • Pfizer Inc.
  • PLx Pharma Inc.
  • Portola Pharmaceuticals, Inc.
  • Sagene Pharmaceuticals, Inc.
  • SciFluor Life Sciences, LLC
  • Zedira GmbH

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • ANV-6L15
  • ARC-15105
  • ASP-6537
  • aspirin
  • BMS-262084
  • BMS-816106
  • BMS-884775
  • CDX-085
  • CLB-100
  • CSL-3F7
  • DD-2
  • Drug for Thrombosis
  • Drug to Activate Endothelial Protein C Receptor for Inflammation and Thrombosis
  • Drugs for Thrombosis
  • DWJ-1261
  • DWJ-1355
  • IMD-4852
  • Ir-CPI
  • ISIS-FVIIRx
  • LC-231306
  • LT-5121
  • LT-5122
  • LT-5521
  • MC-45301
  • MC-45308
  • MC-45350
  • MC-45403
  • Monoclonal Antibodes to Activate TREM-like transcript-1 Receptor for Thrombosis and Hemostasis
  • MSM-236
  • Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction
  • Peptides for Immunology and Cardiovascular Disorders
  • PF-00190434
  • PRT-060318
  • Recombinant Protein for Thrombosis and Non-Small Cell Lung Cancer
  • Recombinant Protein for Thrombosis and Stroke
  • Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis
  • rGPG-290
  • S-002333
  • S-007867
  • selegiline + Antiplatelet Drugs
  • Small Molecule for Thrombosis
  • Small Molecule for Thrombosis
  • Small Molecule to Antagonize P2Y12 for Thrombosis
  • Small Molecule to Inhibit ASK1 for Thrombosis
  • Small Molecule to Inhibit Factor XIa for Thrombosis
  • Small Molecule To inhibit PAR-1 for Atherothrombosis
  • Small Molecules for Hematological Disorders and Cancer
  • Small Molecules for Thrombosis
  • Small Molecules for Thrombosis and Stroke
  • Small Molecules to Inhibit Carboxypeptidase U for Thrombosis
  • Small Molecules to Inhibit Factor XIII for Thrombosis
  • Small Molecules to Inhibit P2Y12 Receptor for Thrombosis
  • Small Molecules to Inhibit PDI for Thrombosis
  • Small Molecules to Inhibit Purinergic Receptor for Thrombosis
  • Small Molecules to Inhibit Thrombin for Thrombosis and Oncology
  • Small Molecules to Inhibit TNF-a for Cardiovascular and CNS Disorders
  • SMRX-11
  • Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury
  • Synthetic Peptides to Inhibit Glycoprotein VI for Thrombosis
  • Tanshinone IIA
  • TM-5275
  • TM-5509
  • TTS-01
  • UM-8190
  • vorapaxar sulfate

パイプライン製品の最新動向

開発休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 注目のニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7204IDB

Summary

Global Markets Direct's, 'Thrombosis - Pipeline Review, H2 2015', provides an overview of the Thrombosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Thrombosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Thrombosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Thrombosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Thrombosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Thrombosis Overview
  • Therapeutics Development
    • Pipeline Products for Thrombosis - Overview
    • Pipeline Products for Thrombosis - Comparative Analysis
  • Thrombosis - Therapeutics under Development by Companies
  • Thrombosis - Therapeutics under Investigation by Universities/Institutes
  • Thrombosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Thrombosis - Products under Development by Companies
  • Thrombosis - Products under Investigation by Universities/Institutes
  • Thrombosis - Companies Involved in Therapeutics Development
    • 3SBio Inc.
    • Antibe Therapeutics, Inc.
    • Archemix Corp.
    • Arena Pharmaceuticals, Inc.
    • Armetheon, Inc.
    • Arrowhead Research Corporation
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Bayer AG
    • Bristol-Myers Squibb Company
    • Cardax Pharmaceuticals, Inc.
    • Cereno Scientific AB
    • China Biologic Products, Inc.
    • CSL Limited
    • Daewoong Pharmaceutical Co., Ltd.
    • Daiichi Sankyo Company, Limited
    • Dyax Corp.
    • Eisai Co., Ltd.
    • F. Hoffmann-La Roche Ltd.
    • Gamma Therapeutics, Inc.
    • Generex Biotechnology Corporation
    • GlycoMimetics, Inc.
    • Green Cross Corporation
    • IMMD Inc.
    • Isis Pharmaceuticals, Inc.
    • Johnson & Johnson
    • Laboratorios Farmaceuticos Rovi, S.A.
    • LG Life Science LTD.
    • Lipicard Technologies Limited
    • Merrion Pharmaceuticals Plc
    • Nihon Pharmaceutical Industry Co., Ltd.
    • Nostrum Pharmaceuticals, LLC
    • Pfizer Inc.
    • PLx Pharma Inc.
    • Portola Pharmaceuticals, Inc.
    • Prothix BV
    • Sagene Pharmaceuticals, Inc.
    • Sanofi
    • SciFluor Life Sciences, LLC
    • The International Biotechnology Center (IBC) Generium
    • Zedira GmbH
    • Zydus Cadila Healthcare Limited
  • Thrombosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AB-012 - Drug Profile
    • alteplase biosimilar - Drug Profile
    • Antisense RNAi Oligonucleotide for DVT - Drug Profile
    • antithrombin III (human) - Drug Profile
    • ANV-6L15 - Drug Profile
    • apixaban - Drug Profile
    • ARC-15105 - Drug Profile
    • ARCF-12 - Drug Profile
    • AS-1468240 - Drug Profile
    • ASP-1645 - Drug Profile
    • ASP-6537 - Drug Profile
    • aspirin - Drug Profile
    • ATB-340 - Drug Profile
    • BAY-1213790 - Drug Profile
    • betrixaban - Drug Profile
    • Biosimilar 4 for Acute Myocardial Infarction, Infertility and Thrombosis - Drug Profile
    • BMS-262084 - Drug Profile
    • BMS-593214 - Drug Profile
    • BMS-654457 - Drug Profile
    • BMS-816106 - Drug Profile
    • BMS-884775 - Drug Profile
    • BMS-986120 - Drug Profile
    • BMS-986141 - Drug Profile
    • BMS-986177 - Drug Profile
    • C-3 - Drug Profile
    • CDX-085 - Drug Profile
    • CSL-312 - Drug Profile
    • DD-2 - Drug Profile
    • Drug to Activate Endothelial Protein C Receptor for Inflammation and Thrombosis - Drug Profile
    • Drugs for Thrombosis - Drug Profile
    • DS-9231 - Drug Profile
    • DWJ-1261 - Drug Profile
    • DWJ-1355 - Drug Profile
    • DX-4012 - Drug Profile
    • E-5539 - Drug Profile
    • edoxaban tosylate - Drug Profile
    • enoxaparin biosimilar - Drug Profile
    • ER-410660 - Drug Profile
    • fondaparinux sodium - Drug Profile
    • fondaparinux sodium - Drug Profile
    • Gammarin - Drug Profile
    • GCC-2107 - Drug Profile
    • GMI-1271 - Drug Profile
    • IMD-4852 - Drug Profile
    • ISIS-FVIIRx - Drug Profile
    • ISIS-FXIRx - Drug Profile
    • JNJ-375 - Drug Profile
    • LC-231306 - Drug Profile
    • LT-5121 - Drug Profile
    • LT-5122 - Drug Profile
    • LT-5521 - Drug Profile
    • Lysimab - Drug Profile
    • Monoclonal Antibody to Inhibit TAFI and PAI-1 for Thrombosis and Stroke - Drug Profile
    • nadroparin calcium - Drug Profile
    • NPB-06 - Drug Profile
    • Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
    • Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
    • PF-00190434 - Drug Profile
    • Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile
    • PRO-01 - Drug Profile
    • Protein for Thromboembolism - Drug Profile
    • PRT-060318 - Drug Profile
    • PZ-128 - Drug Profile
    • Recombinant Protein for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile
    • Recombinant Protein for Thrombosis and Stroke - Drug Profile
    • Recombinant Protein Slit2 to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile
    • Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile
    • rGPG-290 - Drug Profile
    • rivaroxaban - Drug Profile
    • S-002333 - Drug Profile
    • S-007867 - Drug Profile
    • SAR-216471 - Drug Profile
    • selegiline + Antiplatelet Drugs - Drug Profile
    • semuloparin sodium - Drug Profile
    • Small Molecule 2 to Inhibit Factor XIa for Thrombosis - Drug Profile
    • Small Molecule for Thrombosis - Drug Profile
    • Small Molecule for Thrombosis - Drug Profile
    • Small Molecule to Antagonize P2Y12 for Thrombosis - Drug Profile
    • Small Molecule to Antagonize PAR4 for Thromboembolic Disorders - Drug Profile
    • Small Molecule to Inhibit ASK1 for Thrombosis - Drug Profile
    • Small Molecule To Inhibit Factor Xa for Thrombosis - Drug Profile
    • Small Molecule to Inhibit PAR-1 for Atherothrombosis - Drug Profile
    • Small Molecules for Hematological Disorders and Cancer - Drug Profile
    • Small Molecules for Thrombosis - Drug Profile
    • Small Molecules to Inhibit Carboxypeptidase U for Thrombosis - Drug Profile
    • Small Molecules to Inhibit Factor XIa for Stroke and Thrombosis - Drug Profile
    • Small Molecules to Inhibit Factor XIII for Thrombosis - Drug Profile
    • Small Molecules to Inhibit HDAC for Thromboembolism - Drug Profile
    • Small Molecules to Inhibit P2Y12 Receptor for Thrombosis - Drug Profile
    • Small Molecules to Inhibit PDI for Thrombosis - Drug Profile
    • SMRX-11 - Drug Profile
    • Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - Drug Profile
    • Synthetic Peptides to Inhibit Glycoprotein VI for Thrombosis - Drug Profile
    • TAP-ANV - Drug Profile
    • tecarfarin sodium - Drug Profile
    • temanogrel hydrochloride - Drug Profile
    • ticagrelor - Drug Profile
    • TM-5275 - Drug Profile
    • TM-5509 - Drug Profile
    • TRX-1 - Drug Profile
    • TTS-01 - Drug Profile
    • UM-8190 - Drug Profile
    • YG-001 - Drug Profile
  • Thrombosis - Recent Pipeline Updates
  • Thrombosis - Dormant Projects
  • Thrombosis - Discontinued Products
  • Thrombosis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Thrombosis, H2 2015
  • Number of Products under Development for Thrombosis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Development by Companies, H2 2015 (Contd..1)
  • Number of Products under Development by Companies, H2 2015 (Contd..2)
  • Number of Products under Development by Companies, H2 2015 (Contd..3)
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Development by Companies, H2 2015 (Contd..1)
  • Products under Development by Companies, H2 2015 (Contd..2)
  • Products under Development by Companies, H2 2015 (Contd..3)
  • Products under Development by Companies, H2 2015 (Contd..4)
  • Products under Development by Companies, H2 2015 (Contd..5)
  • Products under Investigation by Universities/Institutes, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
  • Thrombosis - Pipeline by 3SBio Inc., H2 2015
  • Thrombosis - Pipeline by Antibe Therapeutics, Inc., H2 2015
  • Thrombosis - Pipeline by Archemix Corp., H2 2015
  • Thrombosis - Pipeline by Arena Pharmaceuticals, Inc., H2 2015
  • Thrombosis - Pipeline by Armetheon, Inc., H2 2015
  • Thrombosis - Pipeline by Arrowhead Research Corporation, H2 2015
  • Thrombosis - Pipeline by Astellas Pharma Inc., H2 2015
  • Thrombosis - Pipeline by AstraZeneca Plc, H2 2015
  • Thrombosis - Pipeline by Bayer AG, H2 2015
  • Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2015
  • Thrombosis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015
  • Thrombosis - Pipeline by Cereno Scientific AB, H2 2015
  • Thrombosis - Pipeline by China Biologic Products, Inc., H2 2015
  • Thrombosis - Pipeline by CSL Limited, H2 2015
  • Thrombosis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
  • Thrombosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
  • Thrombosis - Pipeline by Dyax Corp., H2 2015
  • Thrombosis - Pipeline by Eisai Co., Ltd., H2 2015
  • Thrombosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
  • Thrombosis - Pipeline by Gamma Therapeutics, Inc., H2 2015
  • Thrombosis - Pipeline by Generex Biotechnology Corporation, H2 2015
  • Thrombosis - Pipeline by GlycoMimetics, Inc., H2 2015
  • Thrombosis - Pipeline by Green Cross Corporation, H2 2015
  • Thrombosis - Pipeline by IMMD Inc., H2 2015
  • Thrombosis - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
  • Thrombosis - Pipeline by Johnson & Johnson, H2 2015
  • Thrombosis - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H2 2015
  • Thrombosis - Pipeline by LG Life Science LTD., H2 2015
  • Thrombosis - Pipeline by Lipicard Technologies Limited, H2 2015
  • Thrombosis - Pipeline by Merrion Pharmaceuticals Plc, H2 2015
  • Thrombosis - Pipeline by Nihon Pharmaceutical Industry Co., Ltd., H2 2015
  • Thrombosis - Pipeline by Nostrum Pharmaceuticals, LLC, H2 2015
  • Thrombosis - Pipeline by Pfizer Inc., H2 2015
  • Thrombosis - Pipeline by PLx Pharma Inc., H2 2015
  • Thrombosis - Pipeline by Portola Pharmaceuticals, Inc., H2 2015
  • Thrombosis - Pipeline by Prothix BV, H2 2015
  • Thrombosis - Pipeline by Sagene Pharmaceuticals, Inc., H2 2015
  • Thrombosis - Pipeline by Sanofi, H2 2015
  • Thrombosis - Pipeline by SciFluor Life Sciences, LLC, H2 2015
  • Thrombosis - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015
  • Thrombosis - Pipeline by Zedira GmbH, H2 2015
  • Thrombosis - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Thrombosis Therapeutics - Recent Pipeline Updates, H2 2015
  • Thrombosis - Dormant Projects, H2 2015
  • Thrombosis - Dormant Projects (Contd..1), H2 2015
  • Thrombosis - Dormant Projects (Contd..2), H2 2015
  • Thrombosis - Dormant Projects (Contd..3), H2 2015
  • Thrombosis - Dormant Projects (Contd..4), H2 2015
  • Thrombosis - Dormant Projects (Contd..5), H2 2015
  • Thrombosis - Dormant Projects (Contd..6), H2 2015
  • Thrombosis - Dormant Projects (Contd..7), H2 2015
  • Thrombosis - Dormant Projects (Contd..8), H2 2015
  • Thrombosis - Dormant Projects (Contd..9), H2 2015
  • Thrombosis - Discontinued Products, H2 2015
  • Thrombosis - Discontinued Products (Contd..1), H2 2015
  • Thrombosis - Discontinued Products (Contd..2), H2 2015
  • Thrombosis - Discontinued Products (Contd..3), H2 2015

List of Figures

  • Number of Products under Development for Thrombosis, H2 2015
  • Number of Products under Development for Thrombosis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top